Fujirebio Diagnostics Honored with Pioneer Award from MARF; Company Recognized for Substantial Contributions to Mesothelioma Research And the MESOMARK(TM) Test, the First Blood Test for Mesothelioma.MALVERN, Pa. -- Fujirebio Diagnostics, Inc. (FDI FDI See: Foreign direct investment ), a world-leader in in-vitro diagnostics, was recently honored with a Pioneer Award from the Mesothelioma Applied Research Foundation The Mesothelioma Applied Research Foundation (MARF) is an American national nonprofit organization dedicated to eradicating mesothelioma as a life-ending disease. Their mission is to "eradicate mesothelioma by: MARF Medical Acupuncture Research Foundation MARF Modular Audio Recognition Framework MARF Medical and Actuarial Research Foundation MARF Metadata Archive Retrieval Facility ). FDI, one of several companies presented with a Pioneer Award at MARF's Second International Symposium on Malignant Mesothelioma malignant mesothelioma Mesothelioma, see there , received the award for substantial contributions to mesothelioma Mesothelioma Definition Mesothelioma is an uncommon disease that causes malignant cancer cells to form within the lining of the chest, abdomen, or around the heart. Its primary cause is believed to be exposure to asbestos. research and the MESOMARK(TM) test, the first blood test for mesothelioma. "Fujirebio Diagnostics is committed to providing highly-effective diagnostic tools to better manage this aggressive form of cancer," said Monte Wiltse, vice president of sales and marketing for FDI. "We at Fujirebio Diagnostics thank MARF for the Pioneer Award and look forward to a continued, productive partnership as we make strides together in overcoming this challenging disease." The Pioneer Award features a reproduction of a painting of a compass on a chart by a mesothelioma patient. Chris Hahn, executive director of MARF, explained that the painting symbolically links the pioneer-like journey of mesothelioma patients and researchers today to early American pioneers who explored uninhabited territory for the benefit of others. "With Mesothelioma historically having trouble attracting research dollars from companies, the Pioneer Award is meant to thank and honor companies that have significantly invested in improving outcomes for mesothelioma patients," Hahn said. "Fujirebio Diagnostics is one of the leading biomarker companies in the world. Its investment in this new field of diagnostics improves treatment and life for mesothelioma patients. We're extremely grateful to Fujirebio Diagnostics for its investment in mesothelioma research. We know the award and discussions at the symposium were encouraging to mesothelioma patients and their families in attendance." The MESOMARK test is a manual enzyme-linked immunosorbent assay enzyme-linked immunosorbent assay n. ELISA. Enzyme-linked immunosorbent assay (ELISA) A diagnostic blood test used to screen patients for AIDS or other viruses. (ELISA ELISA (e-li´sah) Enzyme-Linked Immuno-Sorbent Assay; any enzyme immunoassay using an enzyme-labeled immunoreactant and an immunosorbent. ELISA n. ) that works by identifying biomarkers called soluble mesothelin-related peptides (SMRP SMRP - Simplified Multicast Routing Protocol ). These proteins are released into the bloodstream by malignant mesothelioma cells. About Mesothelioma Malignant Pleural Pleural Pleural refers to the pleura or membrane that enfolds the lungs. Mentioned in: Pneumothorax pleural emanating from or pertaining to the pleura. Mesothelioma is a highly aggressive form of cancer found in the lining of the chest, the abdominal cavity abdominal cavity Largest hollow space of the body, between the diaphragm and the top of the pelvic cavity and surrounded by the spine and the abdominal muscles and others. and around the heart, in which fluid accumulates between the lining of the lungs and chest cavity. Mesothelioma is primarily caused by work-related asbestos exposure and has an average latency period of up to 50 years. It is estimated that more than 100 million people worldwide have been occupationally exposed to asbestos in the past five decades. About MARF MARF is a national nonprofit organization dedicated to eradicating mesothelioma as a life-threatening disease. For more information, please visit www.marf.org. About FDI Fujirebio Diagnostics, Inc. (FDI) is a premier diagnostics company and the industry leader in tumor marker assays. FDI specializes in the clinical development, manufacturing and commercialization of in-vitro diagnostic products for the management of human disease states, with an emphasis in oncology. In November 1998, Fujirebio, Inc. of Tokyo, Japan, acquired the company, formerly known as Centocor Diagnostics. FDI utilizes its worldwide distribution network to enable access by physicians and patients to its diagnostic products. For more information about FDI, please call 610-240-3800 or visit www.fdi.com. Forward-Looking Statement Any statements in this press release about future expectations, plans or prospects for the Company, including the Company's expectations and its plans to complete the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval process for MESOMARK constitute forward-looking statements. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. FDI undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect FDI's business. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion